MoonLake Immunotherapeutics reports Q4 EPS (31c), consensus (33c)

Jorge Santos da Silva, CEO of MoonLake Immunotherapeutics, said: "2022 was an excellent year for MoonLake. We went public on Nasdaq, raised $150 million, and initiated two global Phase 2 clinical trials. 2023 looks even more important with results from our two global trials expected during the year. The first Phase 2 trial anticipated to read out is for sonelokimab in HS, a devastating skin disease that can seriously alter the daily lives and emotional well-being of those affected. Recent clinical evidence reported for competitor programs including bimekizumab, secukinumab and izokibep provide us with even greater confidence in our approach and we look forward to announcing the top-line data around the end of June 2023. Our second global Phase 2 trial to read out this year will be for sonelokimab in PsA. This remains on schedule, with top-line results expected at the end of the year. Together with Psoriasis, where we already have data from a large Phase 2 study, we are now looking at Phase 3 readiness in several multi-billion dollar markets."